Stockscreener 앱 받기
2.62
4.03%
-0.11
시간 외 거래:
2.64
0.02
+0.76%
Lisata Therapeutics Inc 주식(LSTA)의 최신 뉴스
Strategic Collaboration with GATC Health Boosts Lisata Therapeutics’ Growth Potential - TipRanks
H.C. Wainwright maintains Lisata Therapeutics stock rating on AI partnership By Investing.com - Investing.com India
Lisata and GATC to use AI for new opioid use disorder drug - The Pharma Letter
Lisata collaborates with GATC Health on drug development - Yahoo Finance
Market movers: T-Mobile, Sunrun, First Solar, Lisata Therapeutics... - Proactive financial news
Lisata Therapeutics to lead development of opioid use disorder drug under expanded alliance - Proactive Investors
Lisata Therapeutics Advances Certepetide for Cancer Treatment - TipRanks
Lisata Therapeutics (LSTA) Partners with GATC Health to Boost Drug Development | LSTA Stock News - GuruFocus
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development | LSTA Stock News - GuruFocus
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development - GlobeNewswire
Lisata Therapeutics Amends Executive Employment Agreements - TipRanks
Lisata Therapeutics to Present at the 2025 BIO International Convention | LSTA Stock News - GuruFocus
Lisata Therapeutics to Present at the 2025 BIO International Convention - The Manila Times
Lisata CEO to Reveal Latest Cancer Treatment Developments at Major Biotech Conference - Stock Titan
Lisata Therapeutics CEO to present at 2025 BIO International Convention - Proactive financial news
Citadel Advisors LLC Makes New $69,000 Investment in Lisata Therapeutics, Inc. (NASDAQ:LSTA) - Defense World
Kalkine : Lisata Therapeutics Earnings Per Share Reflects Biotech Market Trends - Kalkine Media
Lisata Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Lisata Therapeutics (NASDAQ:LSTA) Trading Down 2.2% – What’s Next? - Defense World
Dimensional Fund Advisors LP Increases Stock Position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) - Defense World
Lisata outlines data-rich year ahead with multiple clinical milestones for Certepetide - MSN
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2025 Earnings Call Transcript - Insider Monkey
Lisata Therapeutics’ Earnings Call Highlights Progress - TipRanks
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ... - Yahoo Finance
Earnings call transcript: Lisata Therapeutics sees improved Q1 2025 performance - Investing.com
Lisata Therapeutics Reports Q1 2025 Financial Results - TipRanks
Lisata eyes key trial milestones in 2025 as certepetide development gains momentum - Proactive financial news
Lisata Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025 - The Manila Times
Lisata Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Lisata Therapeutics Earnings: Solid Tumor Treatment Developer Reports Q1 2025 Results May 8 - Stock Titan
Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely? - Yahoo Finance
LSTALisata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Lisata Therapeutics (NASDAQ:LSTA) Shares Up 0.9% – Still a Buy? - Defense World
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI - Proactive financial news
Lisata Therapeutics announces research license with Catalent - MSN
Lisata Therapeutics CMO discusses potential for certepetide under Catalant license agreement - Proactive financial news
Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement - Proactive Investors
Market movers: Meta, HPE, Applied Digital, Lisata Therapeutics... - Proactive Investors
Lisata Therapeutics (LSTA) Partners with Catalent on Preclinical Study | LSTA Stock News - GuruFocus
Lisata Therapeutics Announces Research License with Catalent - GlobeNewswire
Lisata Therapeutics, Inc. Announces Research License with Catalent, Inc - marketscreener.com
Lisata falls after mid-stage data for anticancer agent - MSN
Lisata, Catalent partner for cancer drug research By Investing.com - Investing.com Canada
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’ - marketscreener.com
Neostem stock plunges to 52-week low at $2.01 amid market challenges - Investing.com Australia
Neostem stock plunges to 52-week low at $2.01 amid market challenges By Investing.com - Investing.com South Africa
Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025 - Proactive financial news
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR.com
0.68%
0.50%
자본화:
|
볼륨(24시간):